Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise
beta
Latest Financials
Filings:
By Category
By Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
Company Exhibits:
Indentures
Material Contracts & Credit Agreements
Plans of Reorganization
Articles and Bylaws
Underwriting Agreements
SEC Edgar
Synergy Strips Corp.
SIC 2833 · Medicinal Chemicals & Botanical Products
Notes
Support
about
terms
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
beta
Latest Financials
Filings:
Category
Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
SEC Edgar
Synergy Strips Corp.
SIC 2833 · Medicinal Chemicals & Botanical Products
Notes
Support
about
terms
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
beta
Latest Financials
Filings:
Category
Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
SEC Edgar
Synergy Strips Corp.
SIC 2833 · Medicinal Chemicals & Botanical Products
Notes
Support
about
terms
$
SNYRQ
Synergy Strips Corp.
CIK:
0001562733
|
SEC Filings
Income Statement
Cash Flow
Balance Sheet
v3.26.1
Unaudited Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenue
Total Revenue
$ 5,492,705
$ 8,170,534
Cost of Sales
1,521,910
2,006,513
Gross Profit
3,970,795
6,164,021
Operating expenses
Selling and marketing
2,455,732
2,876,271
General and administrative
2,048,850
1,306,714
Depreciation and amortization
33,333
33,333
Total operating expenses
4,537,915
4,216,318
(Loss) Income from operations
(567,120)
1,947,703
Other (income) expenses
Interest income
(340)
(13,882)
Interest expense
2,012,121
1,095,369
Remeasurement loss on translation of foreign subsidiary
3,718
1,412
Total other expenses
2,015,499
1,082,899
Net (loss) income before income taxes
(2,582,619)
864,804
Income tax benefit
13,720
11,460
Net (loss) income after tax
$ (2,568,899)
$ 876,264
Net (loss) income per share – basic (in Dollars per share)
$ (0.23)
$ 0.1
Net (loss) income per share - diluted (in Dollars per share)
$ (0.23)
$ 0.1
Weighted average common shares outstanding
Basic (in Shares)
11,303,853
8,560,636
Diluted (in Shares)
11,303,853
8,577,620
Comprehensive (loss) income:
Net (loss) income
$ (2,568,899)
$ 876,264
Foreign currency translation adjustment
22,080
(1,935)
Comprehensive (loss) income
(2,546,819)
874,329
Product Sales
Revenue
Total Revenue
5,492,705
6,670,534
License Revenue
Revenue
Total Revenue
$ 1,500,000
v3.26.1
Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Cash Flows from Operating Activities
Net (loss) income
$ (2,568,899)
$ 876,264
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Amortization of debt discount and debt issuance cost
951,942
406,841
Depreciation and amortization
33,333
33,333
Stock based compensation
116,307
Foreign currency transaction loss (gain)
2,684
(3,137)
Remeasurement loss (gain) on translation of foreign subsidiary
3,718
(1,412)
Changes in operating assets and liabilities:
Accounts receivable
1,935,483
940,519
Other receivables
144,637
Loan receivable, related party
(833)
Inventory
355,895
(629,935)
Prepaid expenses
(410,657)
(114,787)
Prepaid expense, related party
(541,467)
(195,913)
Income taxes payable
(2,297)
(165,413)
Contract liabilities
(1,526)
(24,216)
Accounts payable and accrued liabilities
(1,915,323)
(2,218,041)
Accounts payable, related party
(3,871)
129,312
Net cash used in operating activities
(2,044,678)
(822,781)
Cash Flows from Investing Activities
Cash Flows from Financing Activities
Advances from related party
135,000
Repayment of notes payable, related party
(100,000)
Proceeds from notes payable
2,660,000
1,496,250
Payment of loan financing fees
(55,000)
Repayment of notes payable
(2,812,600)
(1,316,572)
Net cash (used in) provided by financing activities
(307,600)
314,678
Effect of exchange rate on cash, cash equivalents and restricted cash
22,080
(1,935)
Net decrease in cash, cash equivalents and restricted cash
(2,330,198)
(510,038)
Cash and restricted cash, beginning of year
2,722,313
787,920
Cash and restricted cash, end of period
392,115
277,882
Cash paid during the period for:
Interest
392,846
573,529
Income taxes
Supplemental Disclosure of Noncash Investing and Financing Activities:
Issuance of common stock for accounts receivable advance financing
117,648
Loan financing fees, accrued
110,000
Capitalized interest on senior debt
400,033
Common stock to be issued for accounts receivable advance financing
$ 153,400
v3.26.1
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2026
Dec. 31, 2025
Current Assets
Cash and cash equivalents
$ 292,115
$ 2,622,313
Restricted cash
100,000
100,000
Accounts receivable, net
1,268,022
3,203,505
Prepaid expenses (including related party amount of $652,270 and $110,803, respectively)
1,303,173
351,049
Inventory, net
3,381,614
3,737,509
Total Current Assets
6,344,924
10,014,376
Intangible assets, net
116,667
150,000
Total Assets
6,461,591
10,164,376
Current Liabilities:
Accounts payable and accrued liabilities (including payable to shareholder of $193,641 and $197,512, respectively)
4,031,994
6,388,219
Income taxes payable
85,811
88,108
Contract liabilities
1,526
Short term loans payable, net of debt discount, related party
100,000
Current portion of notes payable, net of debt discount
2,730,981
1,658,215
Total Current Liabilities
6,848,786
8,236,068
Long-term Liabilities:
Notes payable, net of debt discount
25,018,055
25,056,446
Total long-term liabilities
25,018,055
25,056,446
Total Liabilities
31,866,841
33,292,514
Commitments and contingencies
Stockholders’ Deficit:
Common stock, $0.00001 par value; 300,000,000 shares authorized; 11,483,926 shares issued; 11,303,853 outstanding
114
114
Additional paid in capital
33,710,857
33,594,550
Common stock to be issued
153,400
Accumulated other comprehensive loss
(132,201)
(154,281)
Accumulated deficit
(59,009,920)
(56,441,021)
Less: Treasury stock (180,073 shares) at cost
(127,500)
(127,500)
Total stockholders’ deficit
(25,405,250)
(23,128,138)
Total Liabilities and Stockholders’ Deficit
$ 6,461,591
$ 10,164,376